Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.
In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.
Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | 0.79 Increased by +68.09% | 0.69 Increased by +14.49% |
| Mar 12, 24 | 0.82 Increased by +70.83% | 0.82 |
| Nov 6, 23 | 0.75 Increased by +1.35% | 0.71 Increased by +5.63% |
| Aug 8, 23 | 0.74 Increased by +39.62% | 0.63 Increased by +17.46% |
| May 9, 23 | 0.47 Increased by 0.00% | 0.48 Decreased by -2.08% |
| Feb 21, 23 | 0.48 Increased by +14.29% | 0.47 Increased by +2.13% |
| Nov 8, 22 | 0.74 Increased by +45.10% | 0.51 Increased by +45.10% |
| Aug 9, 22 | 0.53 Decreased by -14.52% | 0.50 Increased by +6.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 195.88 M Increased by +20.81% | 76.82 M Increased by +93.92% | Increased by +39.22% Increased by +60.52% |
| Dec 31, 23 | 230.04 M Increased by +26.75% | 85.39 M Increased by +47.98% | Increased by +37.12% Increased by +16.75% |
| Sep 30, 23 | 216.03 M Increased by +3.38% | 81.84 M Increased by +32.78% | Increased by +37.88% Increased by +28.44% |
| Jun 30, 23 | 221.04 M Increased by +45.07% | 74.75 M Increased by +229.53% | Increased by +33.82% Increased by +127.15% |
| Mar 31, 23 | 162.14 M Increased by +38.25% | 39.62 M Decreased by -34.09% | Increased by +24.43% Decreased by -52.33% |
| Dec 31, 22 | 181.50 M Increased by +77.93% | 57.70 M Decreased by -13.58% | Increased by +31.79% Decreased by -51.43% |
| Sep 30, 22 | 208.98 M Increased by +80.42% | 61.63 M Decreased by -71.54% | Increased by +29.49% Decreased by -84.23% |
| Jun 30, 22 | 152.37 M Increased by +11.66% | 22.68 M Decreased by -75.20% | Increased by +14.89% Decreased by -77.79% |